Effectiveness of HBV Vaccination in Infants and Prediction of HBV Prevalence Trend under New Vaccination Plan: Findings of a Large-Scale Investigation

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Yang, Shi gui ^a   Wang, Bing ^a   Chen, Ping ^a   Yu, Cheng bo ^a   Deng, Min ^a   Yao, Jun ^b   Zhu, Chun xia ^a   Ren, Jing jing ^a   Wu, Wei ^a   Ju, Bin ^c   Shen, Jian feng ^c   Chen, Yu ^a   Li, Ming D ^a   Ruan, Bing ^a   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Zhejiang Geographic Information Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BUILDING WORKER; CHILD; CHINA; COST BENEFIT ANALYSIS; FAMILY HISTORY; FEMALE; FISHERMAN; GENDER; HEPATITIS B; HUMAN; INFANT; MALE; MIGRANT WORKER; OCCUPATION; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; SMOKING; TREND STUDY; VACCINATION; WORKER;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; FORECASTING; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT; MALE; MIDDLE AGED; PREVALENCE; SEX FACTORS; VACCINATION;

EID: 84867662433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047808     Document Type: Article

References (32)

1. Liu J, Fan D, (2007) Hepatitis B in China. Lancet 369: 1582-1583.
2. Torpy JM, Burke AE, Golub RM, (2011) JAMA patient page. Hepatitis B. JAMA 305: 1500.
3. Liaw YF, Chu CM, (2009) Hepatitis B virus infection. Lancet 373: 582-592.
4. WHO (2008) Hepatitis B.
5. Dienstag JL, (2008) Hepatitis B virus infection. N Engl J Med 359: 1486-1500.
6. Kane M, (1995) Global programme for control of hepatitis B infection. Vaccine 13 (Suppl 1):: S47-49.
7. Chen YS, Wang XX, Shang PH, (2007) The study of tendency of hepatitis B virus surface antigen in Chinese population. Chin J Exp Clin Infect Dis 1: 5.
8. Xia GLL, Li CB, Cao HL, Bi SL, Zhan MY, et al. (1996) Prevalence of hepatitis B and C virus infections in the conventional Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int Hepatol Commun 5: 12.
9. Liang X, Bi S, Yang W, Wang L, Cui G, et al. (2009) Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 27: 6550-6557.
10. Lai CL, Ratziu V, Yuen MF, Poynard T, (2003) Viral hepatitis B. Lancet. 362: 2089-2094.
11. Beasley RP, (2009) Development of hepatitis B vaccine. JAMA 302: 322-324.
12. Zhejiang CDC (2007) The plan for implementing supplementary immunization activities for hepatitis B vaccine in Zhejiang Province in 2007-2008. Hangzhou.
13. Statistics ZPBo (2011) The main data bulletin from the sixth national census in Zhejiang province in 2010. In: Statistics ZPBo, editor. Hangzhou.
14. Yao J, Yang JZ, Mo SH, (2000) Investigation on immunization coverage rate and immune effect of hepatitis B vaccine among newborns in Zhejiang province. Chinese Journal of Vaccines and Immunization 6: 4.
15. Yao J, Han XJ, Zhou SC, (1997) Seroepidemiological survey on hepatitis B in Zhejiang province, China. Disease Surveillance 12: 3.
16. Xu XQ, Ling LY, Hu Y, Fu J, (2007) Analysis on the surveillance results of routine immunization in Zhejiang Province from 2000 to 2004. Disease Surveillance 22: 3.
17. Wu GY, Gong YL, Yu SL, Shao RT, Qin HJ, (2004) Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi 25: 474-478.
18. Wittet S (2001) Hepatitis B Vaccine Introduction: Lessons Learned in Advocacy, Communication, and Training.
19. Lee WM, (1997) Hepatitis B virus infection. N Engl J Med 337: 1733-1745.
20. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, et al. (1996) Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117: 313-325.
21. Kuehn BM, (2010) Report: Too little surveillance, treatment for US patients with hepatitis B and C. JAMA. 303: 713-714.
22. Hampton T, (2008) Officials recommend expanded testing for chronic hepatitis B virus infection. JAMA 300: 2108.
23. Razani-Boroujerdi S, Singh SP, Knall C, Hahn FF, Pena-Philippides JC, et al. (2004) Chronic nicotine inhibits inflammation and promotes influenza infection. Cell Immunol 230: 1-9.
24. Muthumani K, Desai BM, Hwang DS, Choo AY, Laddy DJ, et al. (2004) HIV-1 Vpr and anti-inflammatory activity. DNA Cell Biol 23: 239-247.
25. Mogensen TH, Melchjorsen J, Malmgaard L, Casola A, Paludan SR, (2004) Suppression of proinflammatory cytokine expression by herpes simplex virus type 1. J Virol 78: 5883-5890.
26. Lacerda R, Gravato N, McFarland W, Rutherford G, Iskrant K, et al. (1997) Truck drivers in Brazil: prevalence of HIV and other sexually transmitted diseases, risk behavior and potential for spread of infection. AIDS 11 (Suppl 1):: S15-19.
27. Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, et al. (2011) Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 305: 1432-1440.
28. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, et al. (1996) Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 276: 906-908.
29. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, et al. (2007) Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 132: 1287-1293.
30. Yang DB, Ma J, (2004) An Analysis of the Education of the Women's at Child- Bearing Age and the Average Fertility in Guangdong. South China Population 19: 5.
31. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH, (2007) The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 47: 760-767.
32. Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, et al. (2003) Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 8: 531-534.